Tenax Therapeutics Depreciation & Amortization Growth & History (TENX)
Tenax Therapeutics's depreciation and amortization was $0 for fiscal 2024.
View full Tenax Therapeutics company overviewTenax Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $0 | −$8,000 | — |
| 2023 | 2023-12-31 | $8,000 | $2,857 | +55.55% |
| 2022 | 2022-12-31 | $5,143 | $1,027 | +24.95% |
| 2021 | 2021-12-31 | $4,116 | $39 | +0.96% |
| 2020 | 2020-12-31 | $4,077 | −$940 | −18.74% |
| 2019 | 2019-12-31 | $5,017 | −$3,999 | −44.35% |
| 2018 | 2018-12-31 | $9,016 | −$4,605 | −33.81% |
| 2017 | 2017-12-31 | $13,621 | −$5,331 | −28.13% |
| 2016 | 2016-12-31 | $18,952 | −$12,272 | −39.30% |
| 2015 · Dec 31 | 2015-12-31 | $31,224 | — | — |
| 2015 · Apr 30 | 2015-04-30 | $148,140 | −$2,349 | −1.56% |
| 2014 | 2014-04-30 | $150,489 | $1,685 | +1.13% |
| 2013 | 2013-04-30 | $148,804 | −$57,873 | −28.00% |
| 2012 | 2012-04-30 | $206,677 | −$104,349 | −33.55% |
| 2011 | 2011-04-30 | $311,026 | — | — |
Tenax Therapeutics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | −$969 | — |
| Q2 2024 | 2024-06-30 | $0 | −$1,000 | — |
| Q1 2024 | 2024-03-31 | $0 | −$895 | — |
| Q3 2023 | 2023-09-30 | $969 | −$241 | −19.92% |
| Q2 2023 | 2023-06-30 | $1,000 | −$235 | −19.03% |
| Q1 2023 | 2023-03-31 | $895 | −$458 | −33.85% |
| Q3 2022 | 2022-09-30 | $1,210 | $199 | +19.68% |
| Q2 2022 | 2022-06-30 | $1,235 | $344 | +38.61% |
| Q1 2022 | 2022-03-31 | $1,353 | $218 | +19.21% |
| Q3 2021 | 2021-09-30 | $1,011 | $63 | +6.65% |
| Q2 2021 | 2021-06-30 | $891 | −$146 | −14.08% |
| Q1 2021 | 2021-03-31 | $1,135 | $22 | +1.98% |
| Q3 2020 | 2020-09-30 | $948 | −$361 | −27.58% |
| Q2 2020 | 2020-06-30 | $1,037 | −$249 | −19.36% |
| Q1 2020 | 2020-03-31 | $1,113 | −$1 | −0.09% |
| Q3 2019 | 2019-09-30 | $1,309 | −$823 | −38.60% |
| Q2 2019 | 2019-06-30 | $1,286 | −$1,581 | −55.14% |
| Q1 2019 | 2019-03-31 | $1,114 | −$1,461 | −56.74% |
| Q3 2018 | 2018-09-30 | $2,132 | −$1,011 | −32.17% |
| Q2 2018 | 2018-06-30 | $2,867 | −$557 | −16.27% |
| Q1 2018 | 2018-03-31 | $2,575 | −$1,457 | −36.14% |
| Q3 2017 | 2017-09-30 | $3,143 | −$1,677 | −34.79% |
| Q2 2017 | 2017-06-30 | $3,424 | −$1,649 | −32.51% |
| Q1 2017 | 2017-03-31 | $4,032 | −$606 | −13.07% |
| Q3 2016 | 2016-09-30 | $4,820 | −$7,655 | −61.36% |
| Q2 2016 · Jun 30 | 2016-06-30 | $5,073 | −$21,355 | −80.80% |
| Q1 2016 · Mar 31 | 2016-03-31 | $4,638 | −$30,920 | −86.96% |
| Q2 2016 · Oct 31 | 2015-10-31 | $12,306 | −$25,587 | −67.52% |
| Q2 2016 · Sep 30 | 2015-09-30 | $12,475 | — | — |
| Q1 2016 · Jul 31 | 2015-07-31 | $12,650 | −$25,836 | −67.13% |
| Q1 2016 · Jun 30 | 2015-06-30 | $26,428 | — | — |
| Q1 2016 · Mar 31 | 2015-03-31 | $35,558 | — | — |
| Q3 2015 | 2015-01-31 | $35,998 | −$301 | −0.83% |
| Q2 2015 | 2014-10-31 | $37,893 | $260 | +0.69% |
| Q1 2015 | 2014-07-31 | $38,486 | $1,186 | +3.18% |
| Q3 2014 | 2014-01-31 | $36,299 | −$673 | −1.82% |
| Q2 2014 | 2013-10-31 | $37,633 | $952 | +2.60% |
| Q1 2014 | 2013-07-31 | $37,300 | $209 | +0.56% |
| Q3 2013 | 2013-01-31 | $36,972 | −$10,298 | −21.79% |
| Q2 2013 | 2012-10-31 | $36,681 | $8,889 | +31.98% |
| Q1 2013 | 2012-07-31 | $37,091 | −$53,981 | −59.27% |
| Q3 2012 | 2012-01-31 | $47,270 | −$17,049 | −26.51% |
| Q2 2012 | 2011-10-31 | $27,792 | −$29,709 | −51.67% |
| Q1 2012 | 2011-07-31 | $91,072 | −$42,165 | −31.65% |
| Q3 2011 | 2011-01-31 | $64,319 | — | — |
| Q2 2011 | 2010-10-31 | $57,501 | — | — |
| Q1 2011 | 2010-07-31 | $133,237 | — | — |
Tenax Therapeutics depreciation and amortization trends
Over the last five fiscal years, Tenax Therapeutics's depreciation and amortization decreased from $5,017 to $0, a change of −$5,017. The latest reported quarter, Q4 2024, shows $0.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tenax Therapeutics source filings ↗